Similar articles

• Promise of bitter melon (Momordica charantia) bioactives in cancer prevention and therapy.

  Raina K, Kumar D, Agarwal R. Raina K, et al. Semin Cancer Biol. 2016 Oct;40-41:116-129. doi: 10.1016/j.semcancer.2016.07.002. Epub 2016 Jul 21. Semin Cancer Biol. 2016. PMID: 27452666 Free PMC article. Review.
• Guanylate cyclase activity in human leukemic and normal lymphocytes. Enzyme inhibition and cytotoxicity of plant extracts.

  Takemoto DJ, Dunford C, Vaughn D, Kramer KJ, Smith A, Powell RG. Takemoto DJ, et al. Enzyme. 1982;27(3):179-88. doi: 10.1159/000459047. Enzyme. 1982. PMID: 6122565
• Isolation of a guanylate cyclase inhibitor from the balsam pear (Momordica charantia abreviata).

  Vesely DL, Graves WR, Lo TM, Fletcher MA, Levey GS. Vesely DL, et al. Biochem Biophys Res Commun. 1977 Aug 22;77(4):1294-9. doi: 10.1016/s0006-291x(77)80120-4. Biochem Biophys Res Commun. 1977. PMID: 20099 No abstract available.
• Inhibition of growth and guanylate cyclase activity of an undifferentiated prostate adenocarcinoma by an extract of the balsam pear (Momordica charantia abbreviata).

  Claflin AJ, Vesely DL, Hudson JL, Bagwell CB, Lehotay DC, Lo TM, Fletcher MA, Block NL, Levey GS. Claflin AJ, et al. Proc Natl Acad Sci U S A. 1978 Feb;75(2):989-93. doi: 10.1073/pnas.75.2.989. Proc Natl Acad Sci U S A. 1978. PMID: 24847 Free PMC article.
• Bitter melon (Momordica charantia): a review of efficacy and safety.

  Basch E, Gabardi S, Ulbricht C. Basch E, et al. Am J Health Syst Pharm. 2003 Feb 15;60(4):356-9. doi: 10.1093/ajhp/60.4.356. Am J Health Syst Pharm. 2003. PMID: 12625217 Review.